Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RR1: Intra-Arterial Gemcitabine in Pancreatic Cancer
NCT02237157Phase 1Completed
- Sponsor
- RenovoRx
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by RenovoRx. Primary endpoint: Maximum Tolerated Dose. Started Mar 2015; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02237157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237157.